Document is current
Any future updates will be listed below
-
Authors
Lewis, Karl
Ascierto, Paolo
Robert, Caroline
Munhoz, Rodrigo
Liszkay, Gabriella
Marino, Luis De La Cruz
Olah, Judit
Queirolo, Paola
Mackiewicz, Jacek
Shah, Kalpit
Forbes, Harper
Hertig, Christian
Yan, Yibing
Gutzmer, Ralf
McArthur, Grant
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02908672 at ClinicalTrials.govnct02908672 at ClinicalTrials.govDocuments that mention this clinical trial
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
https://doi.org/10.1136/jitc-2021-004226
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of <i>BRAF</i> -mutant advanced melanoma: A matching-adjusted indirect comparison
https://doi.org/10.1136/bmjonc-2025-000912
Response to: ‘Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor’ by Chan and Bass
https://doi.org/10.1136/annrheumdis-2018-213682
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study
https://doi.org/10.1136/jitc-2020-sitc2020.0307
301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
https://doi.org/10.1136/jitc-2020-sitc2020.0301
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Documents that mention this clinical trial
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
https://doi.org/10.1136/jitc-2021-004226
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
https://doi.org/10.1080/14740338.2019.1607289
Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of <i>BRAF</i> -mutant advanced melanoma: A matching-adjusted indirect comparison
https://doi.org/10.1136/bmjonc-2025-000912
Response to: ‘Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor’ by Chan and Bass
https://doi.org/10.1136/annrheumdis-2018-213682
Evolving impact of long-term survival results on metastatic melanoma treatment
https://doi.org/10.1136/jitc-2020-000948
307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study
https://doi.org/10.1136/jitc-2020-sitc2020.0307
301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
https://doi.org/10.1136/jitc-2020-sitc2020.0301
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
- License Information
